Stay Away from Nicholas Bachynsky, Intra-Cellular Hyperthermia (ICHT), and 2,4-Dinitrophenol (DNP)


Stephen Barrett, M.D.
November 18, 2017

Nicholas Bachynsky (1942- ), a medical doctor and twice-convicted criminal whose licenses were revoked in the early 1990s, is largely responsible for the persistance of intracellular hyperthermia {ICHT} as a treatment. This article discusses his treatment theories and warns against reliance on ICHT or anyone who has ever prescribed it.

Bachynsky claims that ICHT is effective against cancer and Lyme disease. During 2003, he oversaw its administration at the Villa Preziosa Medical Facility in Laveno-Mombello, an Italian city near the Swiss/Italian border. The clinic’s now-defunct Web site, which was registered to Life Extensions SA, of Phoenix, Arizona, stated:

Intracellular Hyperthermia Therapy (ICHT) is a patent pending, new method of heat delivery . . . . based on heating cells “from the inside-out.” This is accomplished by uncoupling a basic biologic process known as oxidative phosphorylation. An uncoupling agent is delivered so as to create a short circuit (“futile cycle”) within the inner mitochondrial membrane (mitochondria are intracellular energy producing organelles that make ATP and utilize 95% of all oxygen consumed). This short circuit is created by a biochemical process that shuttles protons back into the mitochondrial matrix and increases heat production at the expense of useful energy (ATP) synthesis. The net result of ICHT therapy is the conversion of mitochondria from efficient “powerhouses” of energy production to “chemical furnaces,” heating cells from the “inside out.”

The dominant effects of hyperthermia appear to be related to the increase in oxygen free radical formation at the level of the mitochondrion. Increased oxygen free radicals induce a series of lethal biochemical events inside the cell that induces death of the cancer cell through either apoptosis or necrosis. Since ICTH initially heats mitochondria, far less heating is required to get the desired effects. Do to their much higher metabolic rates tumor cells are selectively heated to temperatures far greater than that of normal cells.

. . . . Conventional hyperthermia (“outside-in”) heats the exterior of the cell first, and only after going through multiple layers of other tissues. Moreover, ICHT heats tumor cells far in excess of their normal counterparts. This selective heating occurs because the amount of heat produced by uncoupling not only depends on the dose of uncoupler, but also on the metabolic rate of targeted tissues or cells.

Aggressive malignancies have much higher metabolic rates (levels of heat production) than their normal counterparts. In fact, the level of histologic grading (undifferentiation, mitotic index, etc.) correlates directly with metabolic activity. Metabolic rates in some tumors have been shown to be 10 to 30 times greater than their normal counterparts. Thus, if normal cells are uncoupled and heat production is increased four-fold (non-lethal), heat production in tumor cells is increased 4 times their existing metabolic rate, i.e., 40 to 120 fold greater (lethal for many tumors). Conventional hyperthermia heats all cells uniformly and thus has a far smaller therapeutic index and target selectivity [1].

Various Internet postings [2] indicate that Bachynsky’s ICHT involved the intravenous administration of <a href="http://web.archive.org/web/20010524165324/www.princeton.edu/